Other several novel bifunctional agents, including SHR-1701 and YM101, have been developed to counteract resistance to PD-1/PD-L1 inhibitors in lung cancer through simultaneous blockade of both PD-1/PD-L1 and TGF-β pathways [181]. Here, PDCD1 is linked to lung cancer.